跳到主要內容區塊

國立陽明交通大學傳統醫藥研究所

歡迎光臨國立陽明交通大學傳統醫藥研究所

Recent

數據載入中...

藍耿立 副教授

 


姓名:藍耿立

職稱:副教授

電話:(02)2826-7000 #7121
傳真:(02)2822-5044
電子信箱: kllan@ym.edu.tw

學歷:密西根大學藥學院 博士

      國立陽明醫學院醫學系 醫學士

經歷:國立陽明大學醫學院傳醫所 副教授 (現職)

      北榮民總醫院腫瘤醫學部 主治醫師 (現職)

      國立陽明大學醫工學院醫放所 助理教授

      美國德州大學安得森醫院癌症中心 兼任講師

      美國德州大學安德森醫院癌症中心 博士後研究員

學術獎項:

  1. Young Investigator Award Asian Clinical Oncology Society, Gifu Japan (2010)
  2. 學術論文獎 2010-2011年財團法人癌症防治基金會放射腫瘤治療
  3. 台北榮民總醫院醫療創新獎第三名 (2014)
  4. 13屆國家新創獎學研新創獎(國家生技醫療產業策進會2016)
  5. 台北榮民總醫院醫療創新獎第三名 (2017)

研究專長:分子生物及免疫治療研究、癌症新藥開發

研究方向:分子生物及免疫治療研究、癌症新藥開發

開設課程:傳統醫藥學特論、生物科技與製藥產業學、實驗腫瘤治療學

學術論文

1.     Chang CM, Lan KL, Huang WS, Lee YJ, Lee TW, Chang CH, Chuang CM. 188Re-Liposome Can Induce Mitochondrial Autophagy and Reverse Drug Resistance for Ovarian Cancer: From Bench Evidence to Preliminary Clinical Proof-of-Concept. Int J Mol Sci 2017;18.

2.     Kung Y, Lihachev A, Satkauskas S, Lan KL, Chen WS. Electroporation by concentric-type needle electrodes and arrays. Bioelectrochemistry 2017;118:31-37.

3.     Shen YA, Lan KL, Chang CH, Lin LT, He CL, Chen PH, Lee TW, et al. Intraperitoneal (188)Re-Liposome delivery switches ovarian cancer metabolism from glycolysis to oxidative phosphorylation and effectively controls ovarian tumour growth in mice. Radiother Oncol 2016;119:282-290.

4.     Li JJ, Lan KL, Chang SF, Chen YF, Tsai WC, Chiang PH, Lin MH, et al. Development and Characterization of the Recombinant Human VEGF-EGF Dual-Targeting Fusion Protein as a Drug Delivery System. Bioconjug Chem 2015.

5.     Chang YJ, Hsu WH, Chang CH, Lan KL, Ting G, Lee TW. Combined therapeutic efficacy of Re-liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26- murine colon cancer cells. Mol Clin Oncol 2014;2:380-384.

6.     Liu YM, Liu YK, Lan KL, Lee YW, Tsai TH, Chen YJ. Medicinal Fungus Antrodia cinnamomea Inhibits Growth and Cancer Stem Cell Characteristics of Hepatocellular Carcinoma. Evid Based Complement Alternat Med 2013;2013:569737.

7.     Chang YJ, Hsu CW, Chang CH, Lan KL, Ting G, Lee TW. Therapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor model. Invest New Drugs 2013;31:801-811.

8.     Lan KH, Liu YC, Shih YS, Tsaid CL, Yen SH, Lan KL. A DNA vaccine against cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) prevents tumor growth. Biochem Biophys Res Commun 2013;440:222-228.

9.     Lan KH, Wang YW, Lee WP, Lan KL, Tseng SH, Hung LR, Yen SH, et al. Multiple effects of Honokiol on the life cycle of hepatitis C virus. Liver Int 2012;32:989-997.

10.   Hsu CW, Chang YJ, Chang CH, Chen LC, Lan KL, Ting G, Lee TW. Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts. Cancer Biother Radiopharm 2012;27:481-489.

11.   Liu CM, Lee WC, Yu CY, Lan KL, Chang CH, Ting G, Lee TW. Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model. Oncol Rep 2012;27:678-684.

12.   Chen LC, Wu YH, Liu IH, Ho CL, Lee WC, Chang CH, Lan KL, et al. Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. Nucl Med Biol 2012;39:35-43.

13.   Tai SK, Chang HC, Lan KL, Lee CT, Yang CY, Chen NJ, Chou TY, et al. Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages. J Immunol 2012;188:2464-2471.

14.   Lan KH, Shih YS, Chang CA, Yen SH, Lan KL. 5-Fluorocytosine combined with Fcy-hEGF fusion protein targets EGFR-expressing cancer cells. Biochem Biophys Res Commun 2012;428:292-297.

15.   Lan KL, Lan KH, Sheu ML, Chen MY, Shih YS, Hsu FC, Wang HM, et al. Honokiol inhibits hypoxia-inducible factor-1 pathway. Int J Radiat Biol 2011;87:579-590.

16.   Tsai CC, Chang CH, Chen LC, Chang YJ, Lan KL, Wu YH, Hsu CW, et al. Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice. Int J Nanomedicine 2011;6:2607-2619.

17.   Lan KL, Ou-Yang F, Yen SH, Shih HL, Lan KH. Cationic liposome coupled endostatin gene for treatment of peritoneal colon cancer. Clin Exp Metastasis 2010;27:307-318.

18.   Lan KL, Yen SH, Liu RS, Shih HL, Tseng FW, Lan KH. Mutant Bik gene transferred by cationic liposome inhibits peritoneal disseminated murine colon cancer. Clin Exp Metastasis 2007;24:461-470.

19.   Lan KH, Lan KL, Lee WP, Sheu ML, Chen MY, Lee YL, Yen SH, et al. HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines. J Hepatol 2007;46:759-767.

20.   Ou-Yang F, Lan KL, Chen CT, Liu JC, Weng CL, Chou CK, Xie X, et al. Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells. Cancer Res 2006;66:378-384.

21.   Fu Y, Zhong H, Nanamori M, Mortensen RM, Huang X, Lan K, Neubig RR. RGS-insensitive G-protein mutations to study the role of endogenous RGS proteins. Methods Enzymol 2004;389:229-243.

22.   Chen JS, Lan K, Hung MC. Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist Updat 2003;6:129-136.

23.   Wade SM, Lan K, Moore DJ, Neubig RR. Inverse agonist activity at the alpha(2A)-adrenergic receptor. Mol Pharmacol 2001;59:532-542.

24.   Lan KL, Zhong H, Nanamori M, Neubig RR. Rapid kinetics of regulator of G-protein signaling (RGS)-mediated Galphai and Galphao deactivation. Galpha specificity of RGS4 AND RGS7. J Biol Chem 2000;275:33497-33503.

25.   Wade SM, Lim WK, Lan KL, Chung DA, Nanamori M, Neubig RR. G(i) activator region of alpha(2A)-adrenergic receptors: distinct basic residues mediate G(i) versus G(s) activation. Mol Pharmacol 1999;56:1005-1013.

26.   Lan KL, Sarvazyan NA, Taussig R, Mackenzie RG, DiBello PR, Dohlman HG, Neubig RR. A point mutation in Galphao and Galphai1 blocks interaction with regulator of G protein signaling proteins. J Biol Chem 1998;273:12794-12797.

27.   Lan KL, Remmers AE, Neubig RR. Roles of G(o)alpha tryptophans in GTP hydrolysis, GDP release, and fluorescence signals. Biochemistry 1998;37:837-843.

 專利

  1. Lan K-L, Tsai C-L (2017) Novel Conjugates and Uses Thereof US Provisional Filing 62/565,509
  2. 藍耿立,施易昇,張正,顏上惠,藍耿欣(2017) 治療感染性與惡性疾病的標靶化學治療藥物的形成方法, 中華人民共和國發明專利號201210181043.5
  3. 藍耿立,施易昇,張正,顏上惠,藍耿欣(2015) 治療感染性與惡性疾病的標靶化學治療藥物的形成方法, 中華民國(台灣)發明專利核准(發明第 I 486446 )
  4. Chang C, Lan K-L, Wang H-E, Chang S-F, Lee C-J, Jan P-J Dual Targeting Drug Carrier and Application Thereof US Patent Application 14/953,172
  5. 張正、藍耿立、王信二、張順福、李佳哲、詹佩嘉(2015) 雙重標靶融合蛋白; 中華民國(台灣)發明專利核准(發明第 I 496886 )
  6. 藍耿立,施易昇,藍耿欣(2015) 提升感染性與惡性疾病之治療之免疫反應;中華民國(台灣)發明專利核准(發明第 I 602577)
  7. Lan K-L, Shih Y-S, Lan K-H (2013) Method for Enhancing Immune Response in the Treatment of Infectious and Malignant Diseases US Patent: 8609605
  8. Hung M-C, Lan K-L, Lan K-H, Liu J-C, Ou-Yang F (2011) Targeting proteins to deliver therapeutic or diagnostic reagents. US Patent: 7893033

變種基因Bik以微脂體為載體抑制老鼠腹腔擴散腫瘤模型

臺北榮總院內計畫(2006)

Honokiol對缺氧因子的抑制效果

臺北榮總院內計畫(2007)

放射線合併血管內皮細胞生長抑制因子-BikDD基因治療

臺北榮總院內計畫(2008)

融合巨噬細胞集落刺激因子及第二型血管內皮細胞生長因子受體胞外區域融合疫苗之療效探討

臺北榮總院內計畫(2008-2009)

利用抑制血管新生療法以強化放射線治療效果

臺北榮總院內計畫(2009)

融合巨噬細胞集落刺激因子及第二型血管內皮細胞生長因子受體胞外區域之融合疫苗之療效探討

臺北榮總院內計畫(2010)

評估抑制血管新生素的T淋巴細胞關聯蛋白質4與血管內皮細胞生長因子之融合蛋白免疫治療

臺北榮總院內計畫(2010)

優化細胞毒性T淋巴細胞相關抗原DNA疫苗

臺北榮總院內計畫(2011)

分泌可溶性乙型轉化生長因子受體之腫瘤細胞疫苗

臺北榮總院內計畫(2012)

發展程序性死亡‐1( PD‐1)與程序性死亡配體1 (PD‐L1)之抑制劑

臺北榮總院內計畫(2013)

細胞毒殺T 淋巴細胞抗原與血管內皮細胞生長因子受體之融合疫苗

臺北榮總院內計畫(2013)

細胞毒殺T淋巴細胞抗原4(CTLA4)抗體之模擬表位(Mimotopes)篩選

臺北榮總院內計畫(2014)

開發針對癌症幹細胞標記CD133之疫苗

臺北榮總院內計畫(2014)

運用積體光波導表面電漿子共振(SPR)感測晶片偵測胜肽鏈阻止免疫檢查點蛋白與對應受體或配體之交互作用以診斷癌細胞及抗癌藥物開發

北榮-台灣聯合大學計畫 (2014)

轉移性腫瘤動物模型建立及體內放射治療應用研究

原能會補助計畫 (2014)

篩選計畫性死亡受體-1(PD-1)之模擬表位

臺北榮總院內計畫 (2015)

優化DNA疫苗載體以治療感染及腫瘤疾病

北榮-軍醫局補助計畫 (2015)

開發針對CD44模擬胜肽疫苗

臺北榮總院內計畫(2015)

開發針對表皮生長因子受體變體三(EGFRvIII)之疫苗

臺北榮總院內計畫 (2016)

合併放射線治療及針對血管內皮細胞生成生長因子之疫苗

臺北榮總院內計畫(2016)

開發針對白血病抑制因子之疫苗

榮台聯大計畫 (2017)

利用蛋白質設計策略提高免疫細胞因子之抗癌療效

臺北榮總院內計畫(2017-2019)

尋找與白血病抑制因子途徑相關的潛在藥物靶點

榮台聯大計畫 (2018)

創新的血管內皮抑制素及白細胞介素2(endo-IL2)融合蛋白之臨床前療效和毒性研究

科技部補助計畫 (2012-2015)

針對免疫調控點DNA疫苗之前臨床試驗

科技部補助計畫 (2014-2016)

針對表皮生長因子受體(EGFR)之放射標幟表皮生長因子與白蛋白結合區域(EGF-albumin-binding-domain)之融合蛋白藥物

科技部補助計畫 (2015-2017)

發展放射性標記的胞嘧啶脫氨酶與表皮生長因子融合蛋白(Fcy-EGF)以治療表皮生長因子受體(EGFR)表達的癌症

科技部補助計畫 (2018)

本實驗室研究方向:

  • 癌症標靶藥理
  • 癌症放射治療
  • 癌症基因治療

 

 

 

 

 

 

 

瀏覽數  
將此文章推薦給親友
請輸入此驗證碼